Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
CLINIMIX E is a parenteral nutrition solution providing amino acids, electrolytes, and dextrose for intravenous infusion. It supplies essential and non-essential amino acids for protein synthesis, dextrose as a caloric source, and electrolytes for maintenance of acid-base balance and cellular function. Calcium is included for bone health and neuromuscular function.
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% is a parenteral nutrition solution providing amino acids, dextrose, and electrolytes. The amino acids serve as substrates for protein synthesis; dextrose supplies caloric energy; electrolytes maintain acid-base balance and osmotic equilibrium.
Parenteral nutrition for patients requiring intravenous feeding when oral or enteral nutrition is not possible, insufficient, or contraindicated.,Adjunct to other nutritional support in conditions such as gastrointestinal tract obstruction, malabsorption, preoperative bowel rest, or severe catabolic states.
FDA-approved: Parenteral nutrition for patients requiring intravenous nutritional support when oral or enteral nutrition is inadequate or not possible.,Off-label: Adjunctive therapy in catabolic states, burns, trauma.
Administer intravenously. Dose is individualized based on patient's metabolic requirements, clinical condition, and tolerance. Typical adult dose: 500-2000 m L per day, infused at a rate not exceeding 2-3 m L/kg/hour (or 2 mg/kg/min of amino acids), equivalent to 1-1.5 g/kg/day of amino acids and 3-7 g/kg/day of dextrose.
Intravenous infusion: 1-2 L/day as total parenteral nutrition; typical rate 100-125 m L/hour based on caloric and nitrogen needs.
Not applicable as a single entity; components have variable half-lives: dextrose ~1-2h, amino acids ~1-3h for distribution, electrolytes vary. No terminal half-life defined.
Not applicable as a single agent; components have varying half-lives: dextrose ~2 h (glucose), amino acids ~1-3 h (plasma clearance), electrolytes proportional to renal function
Contraindicated in severe renal failure (e GFR < 30 m L/min/1.73 m²) without renal replacement therapy; if used, reduce dose by 50% for moderate impairment (e GFR 30-59 m L/min/1.73 m²) and monitor electrolytes.
Contraindicated in severe renal impairment (Cr Cl <25 m L/min) without CRRT; for Cr Cl 25-50 m L/min reduce volume by 50% and monitor electrolytes; Cr Cl >50 m L/min no adjustment.
CLINIMIX E 4.25/5 contains amino acids, dextrose, and electrolytes, including calcium. No teratogenic effects have been reported in animal or human studies with standard components at physiological concentrations. However, calcium administration in the third trimester may be associated with neonatal hypocalcemia if maternal hypercalcemia occurs. No specific fetal risks are identified for the first two trimesters when used as indicated for parenteral nutrition.
This is a premixed parenteral nutrition solution containing amino acids, dextrose, electrolytes, and calcium. Do not add other medications or supplements without compatibility verification. Monitor serum electrolytes, glucose, and calcium levels regularly. Use inline filter; do not administer if precipitate is present. Contains sulfite-free formulation; safe for sulfite-sensitive patients.
TRAVASOL 4.25% with dextrose 15% is a hypertonic parenteral nutrition solution; must be administered via central venous catheter. Monitor serum electrolytes, glucose, and liver function tests. Adjust rate to avoid hyperglycemia or hypoglycemia. Contains no sulfite, suitable for sulfite-sensitive patients. Check for incompatibilities with other IV additives.
No interactions on record
No interactions on record
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER and TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER are distinct pharmacological agents. CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER belongs to the Parenteral Nutrition Solution class and is primarily used for Parenteral nutrition for patients requiring intravenous feeding when oral or enteral nutrition is not possible, insufficient, or contraindicated.Adjunct to other nutritional support in conditions such as gastrointestinal tract obstruction, malabsorption, preoperative bowel rest, or severe catabolic states.. TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER belongs to the Parenteral Nutrition Solution class and is primarily used for FDA-approved: Parenteral nutrition for patients requiring intravenous nutritional support when oral or enteral nutrition is inadequate or not possible.Off-label: Adjunctive therapy in catabolic states, burns, trauma.. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER carries a safety status of Category C, whereas TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Amino acids are metabolized via transamination and deamination pathways; dextrose is metabolized via glycolysis and the citric acid cycle; electrolytes are not metabolized but are utilized in physiological processes.
Amino acids undergo deamination and transamination in the liver; dextrose is metabolized via glycolysis and the Krebs cycle; electrolytes are excreted or reabsorbed by renal mechanisms.
Excretion depends on amino acid and electrolyte composition; nitrogen waste is eliminated renally as urea. Calcium and magnesium are primarily renally excreted; potassium is mostly renally eliminated. Dextrose is metabolized to CO2 and water. In renal impairment, accumulation may occur.
Renal: 100% (primarily as free water and electrolytes; dextrose is metabolized; amino acids are deaminated and urea is excreted renally)
Low for amino acids and electrolytes; calcium ~40% bound to albumin, magnesium ~30% bound, potassium not protein-bound.
Negligible for most components; amino acids: <20% (primarily albumin); dextrose: none; electrolytes: variable, e.g., calcium ~50% (albumin), magnesium ~30% (albumin)
Not defined as a composite; amino acids distribute into total body water (0.5-0.6 L/kg), calcium distributes into extracellular fluid (~0.2 L/kg), potassium intracellularly (~4 L/kg).
Not applicable as a mixture; approximate Vd for dextrose = 0.2 L/kg (extracellular fluid); electrolytes distribute in total body water (~0.6 L/kg for sodium, ~0.5 L/kg for chloride); amino acids Vd ~0.3-0.5 L/kg
100% (intravenous administration).
I. V. only: 100%
Contraindicated in severe hepatic impairment (Child-Pugh class C); use with caution in Child-Pugh class B (reduce amino acid dose by 50-75%); no adjustment for Child-Pugh class A.
Child-Pugh A: no adjustment; Child-Pugh B: reduce amino acid dose by 50% and monitor ammonia; Child-Pugh C: contraindicated due to risk of encephalopathy.
Dose based on body weight: Amino acids: 1-3 g/kg/day; Dextrose: 5-20 g/kg/day. Initiate at lower end and increase gradually. Typical infusion rate: 1-2 m L/kg/hour, titrate to blood glucose and metabolic tolerance. Not recommended for neonates without risk-benefit assessment.
Starting dose: 0.5-1 g amino acids/kg/day, titrated up to 2-3 g/kg/day based on weight; typical volume 100-150 m L/kg/day for infants; adjust dextrose to maintain euglycemia.
No specific dose adjustment, but use with caution due to potential age-related decline in renal function. Monitor fluid balance and renal function; start at lower doses (e.g., 500 m L/day) and adjust based on tolerance and clinical response.
Start at lower end of dosing range (e.g., 0.5-1 L/day) with slower infusion rate (e.g., 50-75 m L/hour) due to decreased renal clearance; monitor glucose and electrolytes closely.
Not applicable. CLINIMIX E does not carry an FDA black box warning.
Contains sulfites which may cause allergic-type reactions including anaphylactic symptoms and life-threatening asthmatic episodes in susceptible individuals. Sulfite sensitivity is more common in asthmatics.
None; this is an intravenous solution providing nutrition. Do not consume oral nutrients without clinical guidance as it may interfere with nutritional balance.
No direct food interactions, but patients may require adjustments to oral intake during parenteral nutrition transition. Avoid grapefruit juice if certain medications are co-administered (e.g., cyclosporine).
Amino acids, dextrose, and electrolytes in parenteral nutrition are not directly teratogenic. However, the solution is used for maternal nutritional support; no human data on direct fetal risks. Use only if clearly needed. No known structural teratogenicity; potential for metabolic disturbances if maternal homeostasis not maintained.
Safety in breastfeeding is not established. Components excrete into milk in low amounts; no specific M/P ratio available. Parenteral nutrition use in lactating women should be with caution. Monitor infant for electrolyte imbalance.
Excretion into breast milk of components is minimal; no specific M/P ratio reported. Considered compatible with breastfeeding if maternal nutritional status is adequate. Monitor infant for metabolic or electrolyte disturbances only if maternal therapy prolonged.
Pregnancy may increase fluid and electrolyte requirements. Glucose monitoring is essential as gestational diabetes may develop. Calcium dosing may need adjustment to avoid hypercalcemia. No specific dose changes for amino acids; follow standard parenteral nutrition guidelines. Adjust infusion rate based on clinical status and avoid iatrogenic hyperglycemia.
No specific pregnancy pharmacokinetic data. Use standard dosing adjusted for maternal weight and metabolic demands. Monitor glucose tolerance; pregnancy may require increased insulin or reduced dextrose load. Electrolyte needs may increase due to expanded plasma volume; adjust accordingly.
This medication is given through a vein; do not stop or adjust the infusion rate on your own.,Report any signs of infection at the IV site (redness, swelling, pain) or allergic reactions (rash, difficulty breathing).,This solution provides complete nutrition; do not eat or drink without your doctor's approval.,Notify your doctor if you experience nausea, vomiting, headache, or unusual tiredness.
This medication is a form of nutrition given through a vein when you cannot eat.,Your blood sugar and electrolytes will be monitored regularly.,Report any signs of infection (redness, swelling, pain) at the catheter site.,Do not adjust the infusion rate yourself; it is controlled by healthcare staff.,Inform your healthcare provider about all other medications you are taking.